第二世代抗精神病薬市場：適応症別、薬剤クラス別、投与経路別、流通チャネル別、地域別

世界の第二世代抗精神病薬市場は、2025年には102億5,000万米ドルと推定され、2032年には156億7,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR6.25％で成長すると予測されています。

世界の第二世代抗精神病薬市場は、精神疾患の有病率の増加と効果的な治療に対する需要の高まりにより、近年著しい成長を遂げています。非定型抗精神病薬としても知られる第二世代抗精神病薬は、統合失調症、双極性障害、大うつ病性障害など、さまざまな精神疾患の管理に望ましい選択肢として浮上しています。これらの薬剤は第一世代の抗精神病薬と比較して、有効性の向上、錐体外路系副作用の軽減、忍容性の向上などいくつかの利点があります。第二世代抗精神病薬市場は、メンタルヘルスに対する意識の高まり、新規製剤の開発、適応症の拡大などに後押しされ、今後も拡大基調を維持すると予想されます。

市場力学：.

世界の第二世代抗精神病薬市場は、老年人口の増加やメンタルヘルスに対する意識の高まりなど、いくつかの要因によって牽引されています。世界保健機関（WHO）の推計によると、全世界で約4億5,000万人が精神疾患に苦しんでおり、効果的な治療に対する大きな需要が生じています。さらに、第二世代抗精神病薬の長時間作用型注射製剤の開発により、患者のコンプライアンスと利便性が向上し、市場の成長をさらに後押ししています。しかし、これらの薬剤は高価であること、副作用の可能性があること、精神疾患に対する偏見といった市場抑制要因もあります。また、主要薬剤の特許切れやジェネリック医薬品の出現も、市場力学に影響を与える可能性があります。とはいえ、個別化医療への注目の高まり、新規ドラッグデリバリーシステムの市場開拓、他の精神疾患の治療における第二世代抗精神病薬の用途拡大などにより、市場には大きな成長機会が存在します。

本調査の主な特徴

• 本レポートでは、世界の第二世代抗精神病薬市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の第二世代抗精神病薬市場における主要企業プロファイルを掲載しています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の第二世代抗精神病薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者を対象としています。
• 利害関係者は、世界の第二世代抗精神病薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主な発展
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 業界動向

第4章 世界の第二世代抗精神病薬市場、適応症別、2020年～2032年

• 統合失調症
• 双極性障害
• 大うつ病性障害
• 自閉症スペクトラム障害
• その他の適応症

第5章 世界の第二世代抗精神病薬市場、薬剤クラス別、2020年～2032年

• リスペリドン
• クエチアピン
• オランザピン
• アリピプラゾール
• アセナピン
• クロザピン
• パリペリドン
• ブレクスピプラゾール
• ルラシドン
• その他

第6章 世界の第二世代抗精神病薬市場、投与経路別、2020年～2032年

• 経口
• 非経口

第7章 世界の第二世代抗精神病薬市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の第二世代抗精神病薬市場、地域別、2020年～2032年

• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • メキシコ
  • その他ラテンアメリカ
• 欧州
  • ドイツ
  • 英国
  • スペイン
  • フランス
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • ASEAN
  • その他アジア太平洋地域
• 中東
  • GCC諸国
  • イスラエル
  • その他中東
  • 南アフリカ
  • 北アフリカ
  • 中央アフリカ

第9章 競合情勢

• Johnson & Johnson
• Eli Lilly and Company
• AstraZeneca
• Bristol-Myers Squibb
• Pfizer
• Novartis
• Otsuka Pharmaceutical
• Lundbeck
• Sanofi
• Merck & Co.
• AbbVie
• Takeda Pharmaceutical
• Amgen
• GlaxoSmithKline
• Alkermes

第10章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第11章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Second Generation Antipsychotics Market is estimated to be valued at USD 10.25 Bn in 2025 and is expected to reach USD 15.67 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.25% from 2025 to 2032.

The global second generation antipsychotics market has witnessed significant growth in recent years, driven by the increasing prevalence of mental health disorders and the rising demand for effective treatments. Second generation antipsychotics, also known as atypical antipsychotics, have emerged as a preferred choice for the management of various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. These medications offer several advantages over first generation antipsychotics, such as improved efficacy, reduced extrapyramidal side effects, and better tolerability. The market for second generation antipsychotics is expected to continue its upward trajectory, fueled by the growing awareness about mental health, the development of novel formulations, and the expanding indications for these drugs.

Market Dynamic:

The global second generation antipsychotics market is driven by several factors, including the growing geriatric population, and the increasing awareness about mental health. The World Health Organization estimates that around 450 million people globally suffer from mental health disorders, creating a significant demand for effective treatments. Additionally, the development of long-acting injectable formulations of second generation antipsychotics has improved patient compliance and convenience, further driving market growth. However, the market also faces certain restraints, such as the high cost of these medications, the potential for side effects, and the stigma associated with mental health disorders. Patent expiration of key drugs and the emergence of generic alternatives may also impact the market dynamics. Nevertheless, the market presents substantial opportunities for growth, driven by the increasing focus on personalized medicine, the development of novel drug delivery systems, and the expanding applications of second generation antipsychotics in the treatment of other psychiatric disorders.

Key Features of the Study:

• This report provides in-depth analysis of the global second generation antipsychotics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global second generation antipsychotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Lundbeck, Sanofi, Merck & Co., AbbVie, Takeda Pharmaceutical, Amgen, GlaxoSmithKline, and Alkermes
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global second generation antipsychotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global second generation antipsychotics market

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorder
  • Autism Spectrum Disorder
  • Other Indications
• Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Asenapine
  • Clozapine
  • Paliperidone
  • Brexpiprazole
  • Lurasidone
  • Others
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Johnson & Johnson
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb
  • Pfizer
  • Novartis
  • Otsuka Pharmaceutical
  • Lundbeck
  • Sanofi
  • Merck & Co.
  • AbbVie
  • Takeda Pharmaceutical
  • Amgen
  • GlaxoSmithKline
  • Alkermes

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Second Generation Antipsychotics Market, By Indication
  • Global Second Generation Antipsychotics Market, By Drug Class
  • Global Second Generation Antipsychotics Market, By Route of Administration
  • Global Second Generation Antipsychotics Market, By Distribution Channel
  • Global Second Generation Antipsychotics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Second Generation Antipsychotics Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Schizophrenia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bipolar Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Major Depressive Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Autism Spectrum Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Indications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Second Generation Antipsychotics Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Risperidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Quetiapine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Olanzapine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Aripiprazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Asenapine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clozapine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Paliperidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Brexpiprazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lurasidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Second Generation Antipsychotics Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Second Generation Antipsychotics Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Second Generation Antipsychotics Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alkermes
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us